Photo of Angela Crawley

Angela Crawley

Adjunct Research Professors

Degrees:BSc (McGill), PhD (Guelph)
Phone:613 737 8673
Email:acrawley@ohri.ca
Office:The Ottawa Hospital, General Campus, Room C4464
Website:Browse

Current Research

Dr. Angela M. Crawley, Ph.D., is a Scientist in the Chronic Disease Program at the Ottawa Hospital Research Institute (OHRI). She is also an Assistant Professor in the Dept. of Biochemistry, Microbiology and Immunology at the University of Ottawa and Adjunct Research Professor in the Dept. of Biology at Carleton University. She is investigating how chronic hepatitis C virus (HCV) impairs the immune system in HCV mono- and HIV-HCV co-infection. She has recently identified generalized cytotoxic CD8+ T-cell (CTL) impairment in these infections which seems to be worsened in advanced liver fibrosis. This finding extends beyond the weakened responses of these cells in terms of specificity for HCV. Rather, data suggests a concerning widespread immune dysfunction that may contribute to the clinical outcomes of chronic infection such as progressive liver fibrosis, end-stage liver disease and risk for hepatocellular carcinoma. Ongoing research will define the relationship between liver fibrosis and this immune impairment, determine whether it can be reversed with successful anti-viral therapy and investigate whether this is restricted to hepatic viral infections. These investigations will provide insight on the immune parameters of progressive liver fibrosis and will inform new approaches in the prevention of progressive liver disease and the reversal of immune-mediated liver damage. In addition, findings will provide insight for the design of effective T-cell mediating vaccines (including a vaccine to prevent HCV reinfection in those cured of a chronic infection). Lastly, this research will aid in the identification of factors driving adverse clinical outcomes such as liver cancer.

After her undergraduate and graduate training, Dr. Crawley conducted HIV research while training as a postdoctoral fellow in Dr. Jonathan B. Angel’s lab (OHRI), funded in part by an Ontario HIV Treatment Network (OHTN) Fellowship Award. She is the recipient of a CIHR New Investigator Award and an OHTN Junior Investigator Development Award and her research program is supported by independent research grants, including a NSERC Discovery Grant. Dr. Crawley is also an active university professor at all levels.

Selected Publications

Burke, SC., Carrasco-Medina, L., Karges, W., Cooper, CL., Crawley, AM. Generalized liver- and blood-derived CD8+ T cell impairment in response to cytokines in chronic hepatitis C virus infection. PlosOne. 2016 11(6): e0157055.

Corsi, DJ., Karges W., Thavorn K., Crawley AM., Cooper CL. Influence of female sex on hepatitis C virus infection progression and treatment outcomes. European Journal of Gastroenterology and Hepatology. 2016 28(4): 405-411.

Crawley AM., Vranjkovic A., Faller E., McGuinty M., Burke SC., Cousineau S., MacPherson P., Angel JB. Jak/STAT and PI3K signalling pathways have both common and distinct roles in IL-7 mediated activities in human CD8+ T-cellsJ. Leuk. Biol., 2014. 95(1):117-27.

Côté, S., Matte, J., Sad, S., Angel, JB, Crawley AMComplexed soluble IL-7 receptor α and IL-7 increase IL-7-mediated proliferation and viability of CD8+ T-cells in vitro. Cell. Immunol. 2015 293(2):122-125.

Crawley AM., and Angel JB. 2012. The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. (Invited review article for Semin. Immunol., 24:231-240).

PUBMED link: http://www.ncbi.nlm.nih.gov/pubmed?term=Crawley%2C%20Angela[Author]

Recent abstracts at national/international conferences:

Stephanie C. Burke, Lorna Carrasco-Medina, Winston Karges, Curtis L. Cooper, Angela M. Crawley. Generalized CD8+ T cell dysfunction in HCV mono- and HIV-HCV co-infection with pronounced impairment in the liver. (Canadian Association of HIV Researchers Conference, Toronto, ON., May 2015).

Burke, S.C., Cooper, C., Crawley A.M. Evidence of global CD8+ T cell dysfunction in chronic HCV infection with pronounced impairment of liver cells compared to circulating cells. American Association for the Study of Liver Disease – The Liver Meeting (Boston, USA. November 2014).

Steele A.K., Carrasco-Medina L., Sodora D.L., Crawley AM. Increase in soluble IL-7 receptor levels in plasma is associated with improved therapeutic outcome to IL-7 therapy in SIV-infected ART-treated Rhesus macaques. Canadian Association of HIV Research Conference (Toronto, ON. April 2015); International AIDS Symposium (Vancouver, BC. July 2015).

[top]